circle-image

Short

Trend Resistance

Uptrend Above: 23850

Bull Signal Above: 24150
circle-image

Term

Trend Point Acts

Trend Point: 23770

My PCR: 0.57
1370 Range 690

Bear Market Signal

circle-image

View

Trend Suport

Down Below: 23680

Bear Signal Below: 23470
Short Term View Historic Data

Nifty View Tomorrow: Tuesday 29 Sep 2026

Day Close

22780
Day High

23080
Day Low

22762
Day Avg

22874
28 Sep 2026
5 SMA

23152
10 SMA

23212
20 SMA

23483
50 SMA

23963
200 SMA

24400
5 EMA

22964
10 EMA

22994
20 EMA

23122
50 EMA

23362
Tomorrow
Resist 2

23150
Resist 1

22970
Mid Point

22810
Suport 1

22650
Suport 2

22520
52W High

26373
52w Low

22182
52w Down

13.62%
52w Up

2.7%
Panic View
Resist 2

23510
Resist 1

23240
Mid Point

22840
Suport 1

22445
Suport 2

22240
5d High

23489
5d Low

22762
10d High

23592
10d Low

22762
Days High & Low 20d High

24143
20d Low

22762
50d High

24774
50d Low

22762
All Avg

23381
FFTH

23281
FTTL

23039
TTTH

23499
TTTL

23222
High & Low Avg TTFH

23893
TFFL

23433
High Avg

23558
Low Avg

23231
All Avg

23395
Nifty Historic Prediction Data

Nifty Last Five Days Moves

SNo. Date Day Close Day High Day Low 5 DMA 10 DMA 20 DMA 50 DMA 200 DMA
1 28 Sep 2026 22780 23080 22762 23152 23212 23483 23963 24400
2 25 Sep 2026 23140 23162 23020 23278 23274 23553 23994 24417
3 24 Sep 2026 23063 23281 23046 23320 23308 23600 24013 24431
4 23 Sep 2026 23446 23466 23349 23361 23345 23658 24033 24446
5 22 Sep 2026 23329 23489 23285 23315 23364 23702 24045 24459
Nifty Historic Data And Moving Avg

Go Back

Morepen Laboratories Limited Amount and percentage of the turnover or revenue or income and net...

Posted: 14 Jan 2025

Morepen Laboratories Limited Amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year The details of turnover and net worth of Medical Devices Business as on March 31, 2024, are mentioned below: b) Date on which the agreement for sale has been entered into Subject to receipt of requisite regulatory and members’approvals, the Board of Directors of the company hasapproved the sale of the Medical Devices Business of the company to Morepen Medtech Limited, a subsidiary company, as going concern on slump sales basis today i.e.January 14, 2025, including authorising the directors/ officers of the Company to enter the Business TransferAgreement (“BTA”) and other related documents to give effect to the transaction. The BTA will be executed in due course and will be informed to the Stock Exchanges separately. c) Expected date of completion of sale/disposal The completion of the slump sale of the Medical Devices Business is expected to be completed on or before September 30, 2025, subject to receipt of requisite regulatory and other approvals and fulfilment of customary conditions precedent and in accordance with the provisions of the BTA. d) Consideration received from such sale/disposal The consideration for such slump sale will be derived on the basis of the report of the independent valuer in respect of Building and Plant & Machinery, net current assets, other non-current assets and liabilities as per the Balance Sheet as on effective date of transfer of Medical Devices Business and will also be in compliance with Rule 11 UAE of Income Tax Rules 1962. e) Brief details of buyers and whether any of the buyers belong to the promoter/ Morepen Medtech Limited, is a public company (subsidiary of Morepen Laboratories Limited), incorporated on January 8, 2025, to carry on the business of medical devices. Morepen Laboratories Limited CIN NO. L24231 HP1984PLC006028 Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com promoter group/ group companies. If yes, details thereof Yes, Morepen Medtech Limited has been incorporated as a subsidiary of the company, with an aggregate shareholding of 20% of the entities belonging to the promoters’ group/ relatives of promoter/ members of promoter group. f) Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”? Yes, the transaction qualifies as a related party transaction and is being conducted on an arm’s length basis. Furthermore, the company will obtain approval from themembers. g) Whether the sale, lease or disposal of the undertaking is outside the Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations. Yes, the transaction is outside the Scheme of Arrangement.In compliance with Regulation 37A of the SEBI Listing Regulations the “Medical Devices Business” being an“undertaking” in terms of the provisions of the Companies Act, 2013, the company will seek the approval of the members of the company. h) Additional disclosures in case of a ‘slump sale’ i. name of the entity(ies) forming part of the slump sale amalgamation/ merger, details in brief such as, size, turnover etc. Seller: Morepen Laboratories Limited Audited financial details as of March 31, 2024: Particulars Turnover (? in Lakh) Percentage Net worth (? in Lakh) Percentage Other Pharmaceutical Business* 1,24,771.66 73.81% 74,363.57 89.12% Medical Devices Business 44,271.59 26.19% 9,078.52 10.88% Total 1,69,043.25 100.00% 83,442.09 100.00% *Consolidated basis. Buyer: Morepen Medtech Limited, a subsidiary of Morepen Laboratories Limited, as incorporated on January 8, 2025, with the paid-up capital of ? 10,00,000/- (Rupees Ten Lakh Only). ii. whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length” Refer point no. (f) above.

Market Bits

"In investing, what is comfortable is rarely profitable." — Robert Arnott

Be prepared to invest in a down market and to "get out" in a soaring market, as per the philosophy of Warren Buffett.